Apr 26 |
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
|
Apr 25 |
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
|
Apr 25 |
2 Fantastic Growth Stocks to Buy Right Now
|
Apr 25 |
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
|
Apr 24 |
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
|
Apr 23 |
Vertex in-licenses cell therapy technology for diabetes candidates
|
Apr 23 |
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
|
Apr 23 |
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
|
Apr 23 |
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
|
Apr 22 |
10 Best Performing Biotech ETFs in 2024
|